Adjuvant alectinib found to be effective in early-stage ALK-positive non-small cell lung cancer
Hospital Pharmacy Europe
SEPTEMBER 7, 2023
The use of adjunctive alectinib reduced disease recurrence in the early setting for people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) compared to platinum-based chemotherapy, its manufacturer Roche has announced. The OS data were immature at the time of the interim analysis.
Let's personalize your content